|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received March 15, 2004
Revised April 6, 2004
Accepted after revision April 16, 2004
1 Boston Biomedical Research Institute
2 University of Virginia
* To whom correspondence should be addressed. E-mail: kitazawa{at}bbri.org.
Ca2+ sensitivity of arterial contractility is
governed by regulating myosin phosphatase activity in
response to agonist stimuli. CPI-17, a myosin
phosphatase inhibitor phosphoprotein, is phosphorylated
concomitantly with agonist-induced contractile
Ca2+ sensitization in mammalian artery. CPI-
17 was not detected in chicken artery but readily
detected in pigeon artery. To evaluate a role of CPI-
17, we compared contractility of the arteries of "CPI-17-
deficient" chicken with those of CPI-17-rich rabbit and
pigeon, and studied the effect of CPI-17-reconstitution
in chicken artery. Other major regulatory/contractile
proteins for Ca2+ sensitization are expressed
in both chicken and rabbit arteries. Agonists, such as
1-agonist and endothelin-1, produced significant
contraction in arteries of all species under
physiological Ca2+-containing conditions.
Depletion of Ca2+ abolished these
contractions in chicken but partially inhibited them in
rabbit and pigeon arteries. Unlike CPI-17-rich tissues,
chicken arteries exerted little Ca2+
sensitization in response to
1-agonist or
endothelin-1. GTP
S slightly produced
Ca2+ sensitizing effect in chicken artery,
but significantly smaller compared with CPI-17-rich
tissues. A PKC activator (PDBu) did not generate but
rather reduced a contraction in both intact and
-
toxin-permeabilized chicken artery in contrast to a
large contraction in CPI-17-rich arteries. Myosin light
chain phosphorylation was reduced by PDBu in chicken but
elevated in rabbit artery. Addition of recombinant CPI-
17 into
-escin-permeabilized chicken artery
restored PDBu-induced and enhanced GTP
S-induced
Ca2+ sensitization. Thus, CPI-17 is
essential for G protein/PKC-mediated Ca2+
sensitization in smooth muscle.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |